X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALKEM LABORATORIES   ADCOCK INGRAM
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
ADCOCK INGRAM
Jun-14
ALKEM LABORATORIES/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,589399-   
Low Rs1,232288-   
Sales per share (Unadj.) Rs417.5118.8-  
Earnings per share (Unadj.) Rs56.3-29.9-  
Cash flow per share (Unadj.) Rs64.7-24.8-  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.993.3-  
Shares outstanding (eoy) m119.57168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.9 116.8%   
Avg P/E ratio x25.1-11.5 -218.2%  
P/CF ratio (eoy) x21.8-13.9 -157.3%  
Price / Book Value ratio x4.83.7 130.6%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,65358,031 290.6%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m9,1713,642 251.8%   
Avg. sales/employee Rs ThNM4,671.9-  
Avg. wages/employee Rs ThNM848.4-  
Avg. net profit/employee Rs ThNM-1,177.2-  
INCOME DATA
Net Sales Rs m49,91520,056 248.9%  
Other income Rs m1,645140 1,171.3%   
Total revenues Rs m51,56120,197 255.3%   
Gross profit Rs m8,482-3,476 -244.0%  
Depreciation Rs m1,006866 116.2%   
Interest Rs m671543 123.4%   
Profit before tax Rs m8,451-4,744 -178.1%   
Minority Interest Rs m-114-13 860.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606296 541.8%   
Profit after tax Rs m6,731-5,054 -133.2%  
Gross profit margin %17.0-17.3 -98.1%  
Effective tax rate %19.0-6.2 -304.1%   
Net profit margin %13.5-25.2 -53.5%  
BALANCE SHEET DATA
Current assets Rs m27,06214,690 184.2%   
Current liabilities Rs m15,3248,265 185.4%   
Net working cap to sales %23.532.0 73.4%  
Current ratio x1.81.8 99.4%  
Inventory Days Days67111 60.0%  
Debtors Days Days41124 33.3%  
Net fixed assets Rs m12,6108,563 147.3%   
Share capital Rs m23993 256.8%   
"Free" reserves Rs m34,4900-   
Net worth Rs m35,02715,742 222.5%   
Long term debt Rs m1,2125,532 21.9%   
Total assets Rs m54,38729,738 182.9%  
Interest coverage x13.6-7.7 -175.9%   
Debt to equity ratio x00.4 9.8%  
Sales to assets ratio x0.90.7 136.1%   
Return on assets %13.6-15.2 -89.7%  
Return on equity %19.2-32.1 -59.9%  
Return on capital %24.9-19.8 -125.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Net fx Rs m3,5520-   
CASH FLOW
From Operations Rs m7,2591,712 424.0%  
From Investments Rs m1,864-526 -354.6%  
From Financial Activity Rs m-9,2735,021 -184.7%  
Net Cashflow Rs m-1506,207 -2.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.51 Rs / ZAR

Compare ALKEM LABORATORIES With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ALKEM LABORATORIES With: NOVARTIS  SANOFI INDIA  DISHMAN PHARMA  LUPIN LTD  DR. REDDYS LAB  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - ORCHID PHARMA LTD COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS